TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML

Authors

Jayakumar Vadakekolathu, Nottingham Trent University
Michael P. Rettig, washington university school of med
John F. DiPersio, Washington University School of Medicine in St. Louis
et al.

Journal

Blood Advances

Publication Date

2020

Volume

4

Issue

20

First Page

5011

Last Page

5024

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2020002512

Rights and Permissions

Jayakumar Vadakekolathu, Catherine Lai, Stephen Reeder, Sarah E. Church, Tressa Hood, Anbarasu Lourdusamy, Michael P. Rettig, Ibrahim Aldoss, Anjali S. Advani, John Godwin, Matthew J. Wieduwilt, Martha Arellano, John Muth, Tung On Yau, Farhad Ravandi, Kendra Sweet, Heidi Altmann, Gemma A. Foulds, Friedrich Stölzel, Jan Moritz Middeke, Marilena Ciciarello, Antonio Curti, Peter J. M. Valk, Bob Löwenberg, Ivana Gojo, Martin Bornhäuser, John F. DiPersio, Jan K. Davidson-Moncada, Sergio Rutella; TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. Blood Adv 2020; 4 (20): 5011–5024. doi: https://doi.org/10.1182/bloodadvances.2020002512

Recommended Citation

Vadakekolathu, Jayakumar; Rettig, Michael P.; DiPersio, John F.; and al., et, "TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML." Blood Advances. 4, 20. 5011 - 5024. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9848